Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452919 · ClinicalTrials.gov registry record · Phase 3
A Physical Dependence Study in Schizophrenia
A Phase 3 study, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT01452919 is a Phase 3 study that has completed, run by Denovo Biopharma. The registered enrollment target is 123 participants.
The verdict
NCT01452919, a Phase 3 study, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using it. This trial consists of two phases: An open-label phase consisting of up to 4 weeks and a double-blind phase consisting of up to 3 weeks.
Interventions
- DRUG Placebo
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452919
The ClinicalTrials.gov registry entry for NCT01452919 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01452919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452919 about?
NCT01452919 is a clinical study titled "A Physical Dependence Study in Schizophrenia". The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using it. This trial consists of two phases: An open-label phase consisting of...
What is the current status of trial NCT01452919?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2011-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01452919?
The interventions under investigation include: Placebo (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01452919?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.